scholarly journals Defining Incidence, Risk Factors, and Impact on Survival of Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

2013 ◽  
Vol 19 (5) ◽  
pp. 720-724 ◽  
Author(s):  
Joshua Lukenbill ◽  
Lisa Rybicki ◽  
Mikkael A. Sekeres ◽  
Muhammad Omer Zaman ◽  
Alexander Copelan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Hematopoietic Cell Transplantation ◽  
Blood Stream ◽  
Central Line ◽  
Blood Stream Infections ◽  
Impact On Survival ◽  
Incidence Risk ◽  
Acute Myeloid

Defining Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3042-3042 ◽  
Author(s):  
Joshua Lukenbill ◽  
Lisa Rybicki ◽  
Mikkael A. Sekeres ◽  
Megan DiGiorgio ◽  
Thomas Fraser ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Hematopoietic Cell Transplantation ◽  
Blood Stream ◽  
Central Line ◽  
Streptococcus Viridans ◽  
Blood Stream Infections ◽  
Gram Negative ◽  
Definition Of ◽  
Acute Myeloid

Abstract Abstract 3042 Central line-associated blood stream infection (CLABSI) surveillance is increasingly utilized as an objective measure of quality of care provided by individual hospitals. CLABSI is defined by the National Healthcare Safety Network (NHSN) as a primary bloodstream infection (BSI) in a patient with a central line within the 48-hour period before the development of the BSI (NHSN CLABSI). This traditional definition of CLABSI includes pathogens better described as hospital-acquired blood stream infections (HABSI), such as enteric gram-negative bacilli (GNB) and streptococcus viridans - pathogens inherently more common in patients undergoing hematopoietic cell transplantation (HCT) due to the resultant neutropenia and disruption of mucosal barriers, and unlikely to be line-related. To avoid this misclassification, we have developed a modified CLABSI definition (MCLABSI) which excludes HABSI (DiGiorgio, Infect Control Hosp Epidemiol. 33: 865–8, 2012). MCLABSI includes all of the pathogens under the NHSN definition of CLABSI except Viridans group streptococci species in patients with mucositis, and Enterococcus, Enterobacteriaceae, or Candida species in patients with neutropenia or graft-vs-host disease of the gut. We compared the incidence of CLABSI and its impact on survival using both definitions in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients undergoing SCT. AML and MDS patients undergoing HCT between August 2009 and December 2011 were identified from the Cleveland Clinic Unified Transplant Database, and NHSN CLABSI and MCLABSI rates were obtained from the infection control database. CLABSI incidence was estimated using Kaplan-Meier method, and risk factors for mortality were identified using stepwise Cox proportional hazards analyses. Of the 73 patients identified (median age 52, range 16–70), 48 were male, 44 had AML, and 29 MDS. Patients received a median of 2 prior chemotherapy regimens (range 0–6), 3 had prior radiation, and 6 had prior transplant. 54 underwent myeloablative and 19 reduced-intensity preparative regimens; stem cell source included bone marrow (BM, n=34), peripheral stem cells (PSC, n=24), and cord blood cells (CBC, n=15). The median CD34+ count was 2.42 × 106/kg and median time to neutrophil recovery (absolute neutrophil count > 500/μL) was 14 days (range 6–24) with BM/PSC and 28 days (range 19–77) with CBC. Most (88%) had mucositis, including 17 (28%) with grade 3 or 4. Twenty-three (31.5%) developed NHSN CLABSI, compared to 8 (11.0%) who developed MCLABSI following HCT, of whom 16 (69.6%) and 7 (87.5%) died, respectively. The majority (16/23) of NHSN CLABSI occurred within 14 days (median 9 days, range 2–211 days) of HCT (Figure), varying from a median of 5 days (range 2–12 days) for CBC and 78 days for BM/PSC (range 7–211 days, p<.001). Pathogens in NHSN CLABSI included 11 enteric Gram-negative bacilli, 7 Streptococcus viridans group, 6 enterococcus (3 vancomycin resistant), 5 Staphylococcus (3 methicillin resistant), 2 fungal species, 2 Gram-positive bacilli, 1 Pseudomonas, 1 other Streptococcus species, and 1 Stenotrophomonas. MCLABSI occurred a median of 12 days (range 5–176 days) from HCT (Figure), 7 days for CBC (range 5–12 days) compared to 77 days (range 13–176 days) for BM/PSC (p<.001). Pathogens isolated in MCLABSI included 5 Staphylococcal species (3 MRSE), 2 Streptococcus viridans group, 2 GPB, 1 VRE, and 1 Pseudomonas. 4 NHSN CLABSI and 2 MCLABSI were polymicrobial, and 4 patients had recurrent CLABSI (all of whom died, including 3 MCLABSI). When NHSN CLABSI was analyzed as a time-varying covariate in univariable analysis, it was associated with an increased risk of mortality (HR 3.72, 95% CI 1.88 – 7.36, p<.001), as was MCLABSI (HR 2.96, CI 1.27–6.89, p=.012). CLABSI remained a significant risk factor for mortality in multivariable analysis, by both the NHSN (HR 7.14, CI 3.31 – 15.31, p<.001) and MCLABSI (HR 6.44, CI 2.28–18.18, p<.001) definitions. CLABSI is a common complication in AML and MDS patients undergoing SCT, and is associated with decreased survival. CLABSI is identified less commonly with the exclusion of HABSI in the modified definition, which more precisely identifies patients with BSI related to their central lines. The distinction between these definitions is important to guide preventative infectious control measures, particularly given CLABSI's role as a quality measure influencing reimbursement. Disclosures: Hill: Teva Pharmaceuticals: Honoraria, Speakers Bureau.

Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Incidence, Risk Factors, and Impact On Survival

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4481-4481
Author(s):  
Joshua Lukenbill ◽  
Lisa Rybicki ◽  
Mikkael A. Sekeres ◽  
Alexander Copelan ◽  
Omer Zaman ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cord Blood ◽  
Myeloid Leukemia ◽  
Hematopoietic Cell Transplantation ◽  
Blood Stream ◽  
Central Line ◽  
Impact On Survival ◽  
Incidence Risk ◽  
Comorbidity Index ◽  
High Comorbidity

Abstract Abstract 4481 Patients undergoing hematopoietic cell transplantation (HCT) require central venous access during treatment, predisposing this inherently susceptible population to infection. Central line-associated blood stream infection (CLABSI) is defined by the National Healthcare Safety Network as a primary bloodstream infection (BSI) in a patient with a central line within the 48-hour period before the development of the BSI. CLABSI surveillance is being increasingly used as an objective measure of quality of care delivered at individual hospitals. The Centers for Disease Control and Prevention have developed guidelines for the insertion, surveillance, and timely removal of these lines to prevent CLABSI, of which approximately 10% are fatal, and the Centers for Medicare & Medicaid will adjust reimbursement for CLABSI. The incidence, risk factors, and impact on survival of CLABSI in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients undergoing HCT has not been reported. AML or MDS patients undergoing HCT between August 2009 and December 2011 were identified from the Cleveland Clinic Unified Transplant Database, and occurrence of CLABSI was determined from the infection control database. Variables analyzed included occurrence of CLABSI, as well as patient demographics, disease type, prior treatment, HCT comorbidity index, transplant type/HLA-match, CD34+ count, and time to neutrophil recovery (absolute neutrophil count >500). CLABSI incidence was estimated using Kaplan-Meier method, and univariable and multivariable risk factors were identified by Cox proportional hazards analyses. Of the 73 patients identified, 48 were male; 68 were Caucasian; 44 had AML, and 29 MDS. The median age at transplant was 52 (range 16–70), and 39 had a low to intermediate HCT comorbidity index (0–2), while 34 had a high index (≥3). Patients received a median of 2 prior chemotherapy regimens (range 0–6), 3 had prior radiation, and 6 had prior transplant. Preparative regimen was myeloablative (n=54) or reduced-intensity (n=19); 34 received bone marrow (BM), 24 peripheral stem cells (PSC), and 15 cord blood cells (CBC). The median CD34+ count was 2.42 × 106/kg and median time to neutrophil recovery was 14 days (range 6–24) with BM/PSC compared to 28 days with CBC (range 19–77). Among these 73 patients, 23 (31.5%) developed CLABSI, of whom 16 (69.6%) died. The majority (16/23) of CLABSI occurred within 14 days (median 9 days, range 2–211 days) from HCT (Figure 1), but timing of CLABSI was highly associated with cell source: median of 5 days (range 2–12 days) for CBC and 78 days (range 7–211 days) for BM/PSC (p<.001). Etiologies of CLABSI included 11 enteric Gram-negative bacilli, 7 Streptococcus viridans group, 6 enterococcus (3 vancomycin resistant), 5 Staphylococcus (3 methicillin resistant), 2 fungal species, 2 Gram-positive bacilli, 1 Pseudomonas, 1 other Streptococcus species, and 1 Stenotrophomonas. 4 patients had polymicrobial infections, and 5 (all of whom died) had more than one separately documented CLABSI. Univariable risk factors for CLABSI included cord blood transplant (p<.001), HLA-mismatch (p=.005), low CD34+ count (p=.007), and non-Caucasian race (p=.017). Risk factors for CLABSI in multivariable analysis were CBC (p<.001) and high comorbidity index (p=.002); 4 distinct populations of patients were created based on this data, ranging from a high comorbidity index/cord blood cohort to a low to intermediate co-morbidity index/marrow cohort (Figure 2). When CLABSI was analyzed as a time-varying covariate in univariable analyses, it was associated with an increased risk of mortality (HR 3.17, 95% CI 1.61–6.22, p<.001). Multivariable risk factors for mortality included CLABSI (HR 7.14, CI 3.31 – 15.37, p<.001), MDS diagnosis (HR 5.21, CI 2.40–11.33, p<.001), and age (HR 1.81, CI 1.21–2.71, p=.004). CLABSI is a common complication in AML and MDS patients undergoing HCT, and is associated with remarkably decreased survival. Cord blood, perhaps related to the extent and duration of severe immune deficiency, and high HCT comorbidity index place patients at higher risk of CLABSI. Efforts to identify patients at high risk of CLABSI, careful adherence to preventative infectious control measures, and design of methods to enhance immune reconstitution post-transplant in the high risk population could improve outcome in a substantial portion of patients. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults

Hematology ◽  
2014 ◽  
Vol 2014 (1) ◽  
pp. 21-33 ◽  
Author(s):  
Mohamed L. Sorror ◽  
Elihu Estey
Keyword(s):  
Risk Factors ◽  
Acute Myeloid Leukemia ◽  
Cell Transplantation ◽  
Myeloid Leukemia ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Assessment Tools ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Patient Specific ◽  
Acute Myeloid

Abstract Acute myeloid leukemia (AML) is primarily a disease of the elderly and the numbers of these patients are increasing. Patients ≥60 years of age continue to have poor prognosis. Preliminary results suggest benefit from reduced-intensity allogeneic hematopoietic cell transplantation (HCT) in selected patients 60-80 years of age. However, although patients in this age range comprise >50% of those with AML, they currently constitute only 17% of those offered HCT. In the absence of prospective randomized studies comparing HCT and chemotherapy, the decision to recommend HCT rests on retrospective analyses of the risks of relapse and nonrelapse mortality after each approach. There is strong evidence that pre-HCT comorbidities can predict HCT-related morbidity and mortality. Age alone does not appear predictive and, particularly if the risk of relapse with chemotherapy is high, should not be the sole basis for deciding against HCT. Use of geriatric assessment tools, inflammatory biomarkers, and genetic polymorphism data may further aid in predicting nonrelapse mortality after HCT. Disease status and pretreatment cytogenetics with FLT3-TID, NPM-1, and CEBP-α status are the main factors predicting relapse and these are likely to be supplemented by incorporation of other molecular markers and the level of minimal residual disease after chemotherapy. HLA-matched related and unrelated donor grafts seem preferable to those from other donor sources. Donor age is of no clear significance. Models combining comorbidities with AML risk factors are useful in risk assessment before HCT. In this chapter, we integrated information on AML-specific, HCT-specific, and patient-specific risk factors into a risk-adapted approach to guide decisions about HCT versus no HCT.

Sign in / Sign up

Export Citation Format

Share Document